Leite John, an insider at Veracyte Inc (VCYT), executed a significant sale of 86,291 shares on November 24, 2025, at a price of $50.00 per share, resulting in a total transaction value of $4.31 million. Following this transaction, Leite retains 86,291 shares of the company.
Veracyte operates in the biotechnology sector, focusing on the research, development, and commercialization of diagnostic products. The firm, headquartered in South San Francisco, California, employs 824 full-time staff and went public on October 30, 2013. Veracyte's Diagnostics Platform provides cancer tests supported by extensive genomic and clinical data, advanced bioinformatics, and artificial intelligence capabilities. The company offers tests for various cancers, including prostate (Decipher Prostate), thyroid (Afirma), breast (Prosigna), and bladder (Decipher Bladder), along with the noninvasive Percepta Nasal Swab test for lung cancer risk assessment.
As of November 8, 2025, Veracyte boasts a market capitalization of $3.3 billion, with a trailing twelve-month price-to-earnings ratio of 125.14 and earnings per share of 0.33. Upcoming earnings reports are scheduled for May 5, 2026, and August 4, 2026, with estimated EPS of $0.23 and $0.30, respectively.
Insider transactions are reported to the SEC and can provide insights into how executives perceive their company's stock. However, such sales should be viewed in context, as they may stem from personal financial considerations rather than negative sentiment regarding the company's prospects. Investors are encouraged to assess broader patterns of insider activity across multiple individuals and time frames, rather than relying solely on isolated transactions.